A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of generic Febuxostat 80 mg tablets relative to Feburic 80 mg in healthy Thai volunteers under fasting condition

Authors
Category Primary study
Registry of TrialsThai Clinical Trials Registry
Year 2025
This article has no abstract
Epistemonikos ID: d548ac900606aa88ed4964cc67d802ed40bb01ff
First added on: Apr 24, 2026